Johnson & Johnson (JNJ)

Industry Drug Manufacturers - General

This stock can be held in an Investment ISA and an Investment Account

Sell

$143.68

Buy

$143.71

arrow-down$-0.77 (-0.53%)

Prices updated at 23 Dec 2024, 17:38 EST

Prices minimum 15 mins delay

Prices in USD

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices segments.

S&P 500

0.24%

NYSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Drug Manufacturers - General

Chairman

Mr. Timothy Schmid

CEO

Mr. Joaquin Duato

Most recent earnings

31 Dec 2023

Fiscal year end

31 Dec 2023

Employees

134,400

Head office

One Johnson and Johnson Plaza

New Brunswick

United States

08933

+1 732 524-0400

investor-relations@its.jnj.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Kristen Mulholland Chief Human Resources Officer	-
Ms. Anne M. Mulcahy Lead Independent Director	0.20m
Dr. John C. Reed,M.D.,PhD Executive Vice President, Innovative Medicine, R&D	0.84m
Ms. Marillyn A. Hewson Independent Director	0.15m
Dr. Paula A. Johnson,M.D. Independent Director	0.11m
Mr. Hubert Joly Independent Director	0.13m
Dr. Mary C. Beckerle, PhD Independent Director	0.15m
Mr. Darius E. Adamczyk Independent Director	0.13m
Dr. Mark B. McClellan, M.D.,PhD Independent Director	0.13m
Mr. Joaquin Duato Chairman of the Board and Chief Executive Officer	1.58m
Dr. Jennifer A. Doudna, PhD Independent Director	0.13m
Mr. Joseph J. Wolk, C.P.A. Executive Vice President and Chief Financial Officer	1.15m
Mr. James D. Swanson Executive Vice President and Chief Information Officer	-
Ms. Jennifer L. Taubert Executive Vice President and Worldwide Chairman, Innovative Medicine	1.13m
Ms. Kathryn E. Wengel Executive Vice President and Chief Technical Operations & Risk Officer	-
Mr. Eugene A. Woods Independent Director	0.01m
Dr. Nadja Y West, M.D. Independent Director	0.13m
Mr. Mark A. Weinberger Independent Director	0.15m
Mr. Robert J. Decker, Jr Controller and Chief Accounting Officer	-
Mr. William N. Hait, M.D.,PhD Executive Vice President, Chief External Innovation and Medical Officer	-
Ms. Vanessa Broadhurst Executive Vice President, Global Corporate Affairs	-
Ms. Elizabeth Forminard Executive Vice President and General Counsel	-
Mr. Timothy Schmid Executive Vice President and Worldwide Chairman, MedTech	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Vanguard Group Inc	231,019,853
BlackRock Inc	198,186,824
State Street Corp	134,245,811
Vanguard Investments Australia Ltd	77,544,644
Vanguard US Total Market Shares ETF	76,276,335

Director dealings

Date chevron-l-regular chevron-r-regular	Action
05 Dec 2023	-
07 Sep 2023	-
23 Aug 2023	-
23 Aug 2023	-
23 Aug 2023	-
23 Aug 2023	-
23 Aug 2023	-
26 Jul 2023	-
26 Jul 2023	-
26 Jul 2023	-
25 Jul 2023	-
12 Jun 2023	-
06 Jun 2023	-
24 May 2023	-
27 Apr 2023	-
27 Apr 2023	-
27 Apr 2023	-
27 Apr 2023	-
27 Apr 2023	-
27 Apr 2023	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.